Scientific Advisory Board BioCurex’s Scientific Advisory Board includes the creators of the cancer marker diagnostics field: Dr. Phil Gold, C.C., O.Q., M.D., and Ph.D, Dr. Garri Abelev Ph.D (Russia), who discovered the first cancer marker, AFP, present in liver cancers. Dr. Phil Gold, C.C., O.Q., M.D., Ph.D. His early research led to the discovery and definition of the Carcinoembryonic Antigen (CEA), the blood test most frequently used in the diagnosis and management of patients with cancer. Dr. Jose Uriel, Ph.D., M.D., Dr. Uriel has worked at the Pasteur Institute and was research director of the prestigious CNRS. He also worked at the Laboratory of Immunology, NIH Bethesda, MD. From 1963 to 1995, he directed the laboratory of protein chemistry at the French Research Cancer Institute of which he was later the Director. In 1970 he received the prestigious Rosen Award in cancer research and in 1972 became laureate of the French National Academy of Medicine (Leon Berat Prize). Dr. Uriel has published more than 220 scientific papers and written several chapters in books related to cancer research. Dr.Uriel has made major contributions to the understanding of the physiology of AFP and cancer markers. Dr. Garry Abelev. In 1963 Dr. Abelev first described the association between alfa-fetoprotein (AFP) and liver cancer. This was the first cancer marker of clinical use ever reported. His work launched the entire field of tumor markers into the multi-billion dollar industry it is today and he is considered the Dean of the cancer marker community. Dr. Abelev has contributed in very significant ways to the understanding of the functions of AFP. He continues his work in a very active way in his laboratory at the Cancer Research Center, immunochemistry division in Moscow. Dr. M.J. Villacampa, Ph.D., Dr. Villacampa is a full professor at the department of biochemistry and cellular and molecular biology at the University of Zaragoza in Spain. She was part of the team that initially characterized RECAF and has published a significant number of papers related to the different aspects of this molecule in collaborations with Dr. Uriel and Dr. Moro. Dr. T. Tamaoki, Ph.D., Dr. Tamaoki obtained his degree in 1960 at the University of Wisconsin. He moved to the University of Alberta, cancer research unit where he worked as associate professor and then faculty professor at the University of Calgary. He held positions as research associate of the National Cancer Institute of Canada and at the Terry Fox Cancer Research Institute. Tamaoki is a molecular biologist and it was in his laboratory that alpha-fetoprotein (AFP) was cloned for the first time. His paper was published in the prestigious journal, Proceedings of the National Academy of Sciences. He is regarded as the worldwide authority in AFP structure. Dr. E. Alpert, M.D., Ph.D. is a member of the New York Academy of Sciences. Dr. Alpert is one of the pioneers in the field of AFP and cancer markers. He has made significant contributions to this field. Dr. Alpert is in charge of the workshop for evaluation of cancer markers for the International Society of Onco-Developmental Biology and Medicine. Dr. Michael Sadelain, M.D., Ph.D., Director of one of the handful of gene therapy units approved by the FDA in the United States (Sloan-Kettering Memorial, National Cancer Institute, USA) The laboratory he manages is actively involved in genetic engineering applied to the immune system, a combination of fields that will prove valuable for future work on RECAF. Dr. Sadelain has previously worked together with Dr. Moro using RECAF in experiments showing complete abrogation of tumor growth in animal models. Dr. Stewart Sell, M.D. is recognized internationally as an authority and pioneer in stem cell research, having received the Virchow Award for his contribution to the understanding of adult stems cells in repair of tissue injury and the role of stem cells in the development and progression of cancer. |